BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,169,228 | -18.4% | 252,229 | -2.2% | 0.02% | -19.0% |
| Q2 2023 | $21,051,561 | +4.4% | 257,890 | -5.1% | 0.02% | +5.0% |
| Q1 2023 | $20,155,494 | -7.4% | 271,674 | +3.5% | 0.02% | -13.0% |
| Q4 2022 | $21,757,160 | +25.9% | 262,514 | +331.4% | 0.02% | +21.1% |
| Q3 2022 | $17,283,000 | -17.2% | 60,856 | +1.1% | 0.02% | -13.6% |
| Q2 2022 | $20,874,000 | -22.7% | 60,220 | -3.4% | 0.02% | -4.3% |
| Q1 2022 | $26,989,000 | -9.3% | 62,328 | +8.4% | 0.02% | +43.8% |
| Q4 2021 | $29,756,000 | +5.8% | 57,516 | -0.9% | 0.02% | +6.7% |
| Q3 2021 | $28,124,000 | +7.3% | 58,039 | -0.3% | 0.02% | +7.1% |
| Q2 2021 | $26,200,000 | +50.1% | 58,191 | +27.3% | 0.01% | +55.6% |
| Q1 2021 | $17,454,000 | +11.0% | 45,696 | -7.7% | 0.01% | +12.5% |
| Q4 2020 | $15,728,000 | +79.7% | 49,529 | +40.2% | 0.01% | +60.0% |
| Q3 2020 | $8,754,000 | -46.8% | 35,335 | -43.3% | 0.01% | -58.3% |
| Q2 2020 | $16,458,000 | +51.3% | 62,325 | +8.6% | 0.01% | +33.3% |
| Q1 2020 | $10,880,000 | +22.7% | 57,378 | +42.0% | 0.01% | +50.0% |
| Q4 2019 | $8,869,000 | +77.3% | 40,402 | +58.0% | 0.01% | +50.0% |
| Q3 2019 | $5,002,000 | -28.3% | 25,563 | -23.6% | 0.00% | -33.3% |
| Q2 2019 | $6,981,000 | +1.8% | 33,481 | -3.1% | 0.01% | 0.0% |
| Q1 2019 | $6,858,000 | +50.6% | 34,539 | +9.8% | 0.01% | +20.0% |
| Q4 2018 | $4,553,000 | -38.1% | 31,466 | -12.7% | 0.01% | -28.6% |
| Q3 2018 | $7,360,000 | +36.4% | 36,060 | -1.1% | 0.01% | +40.0% |
| Q2 2018 | $5,396,000 | -14.4% | 36,471 | -12.7% | 0.01% | -16.7% |
| Q1 2018 | $6,307,000 | +13.1% | 41,759 | -3.0% | 0.01% | +20.0% |
| Q4 2017 | $5,578,000 | +3.1% | 43,059 | -3.8% | 0.01% | 0.0% |
| Q3 2017 | $5,411,000 | +20.5% | 44,760 | +17.1% | 0.01% | +25.0% |
| Q2 2017 | $4,492,000 | +10.0% | 38,225 | -4.9% | 0.00% | 0.0% |
| Q1 2017 | $4,085,000 | -17.7% | 40,203 | -16.7% | 0.00% | -20.0% |
| Q4 2016 | $4,963,000 | -15.7% | 48,267 | -10.2% | 0.01% | -16.7% |
| Q3 2016 | $5,884,000 | +1.6% | 53,730 | +4.6% | 0.01% | 0.0% |
| Q2 2016 | $5,790,000 | +32.9% | 51,344 | +11.4% | 0.01% | +20.0% |
| Q1 2016 | $4,358,000 | +3.3% | 46,095 | -1.7% | 0.01% | 0.0% |
| Q4 2015 | $4,220,000 | +7.1% | 46,879 | +10.0% | 0.01% | 0.0% |
| Q3 2015 | $3,940,000 | -63.1% | 42,619 | -60.7% | 0.01% | -50.0% |
| Q2 2015 | $10,673,000 | +7.2% | 108,403 | +9.2% | 0.01% | 0.0% |
| Q1 2015 | $9,957,000 | +19.0% | 99,292 | +9.6% | 0.01% | +42.9% |
| Q4 2014 | $8,370,000 | – | 90,585 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |